Nippon India Pharma Fund - Growth - Direct Plan

Other Plans and Options
  • (-0.22%)Nav, as on 21-03-2023

  • Previous Nav

  • Net Change on 21-03-2023

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth -1.92 -5.49 -6.84 24.76 15.57 14.98
S&P BSE Health Care - TRI -2.87 -8.93 -11.01 22.10 10.65 12.63
S&P BSE SENSEX - TRI -4.28 -4.74 2.69 26.18 13.19 13.16

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth Jan 01, 2013 -6.84 24.76 15.57 1.26 4,267.60
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH Jan 01, 2013 -1.40 25.72 13.56 1.09 1,574.52
UTI Healthcare Fund - Direct Plan - Growth Option Jan 01, 2013 -8.50 22.16 12.00 1.50 655.16
Tata India Pharma & Healthcare Fund-Direct Plan-Growth Dec 28, 2015 -7.74 21.89 14.84 1.01 485.91

Fund Holdings as on 28-February-2023

  • Sun Pharmaceutical Industries Limited

  • Dr. Reddy's Laboratories Limited

  • Lupin Limited

  • Cipla Limited

  • Apollo Hospitals Enterprise Limited

  • Narayana Hrudayalaya Limited

  • Abbott India Limited

  • Divi's Laboratories Limited

  • Aurobindo Pharma Limited

  • Zydus Lifesciences Limited

  • Torrent Pharmaceuticals Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Fortis Healthcare Limited

  • Gland Pharma Limited

  • Sanofi India Limited

  • Ajanta Pharma Limited

  • Pfizer Limited

  • Vijaya Diagnostic Centre Limited

  • Alkem Laboratories Limited

  • Thyrocare Technologies Limited

  • MedPlus Health Services Limited

  • Indoco Remedies Limited

  • IPCA Laboratories Limited

  • Syngene International Limited

  • Orchid Pharma Limited

  • Triparty Repo

  • GlaxoSmithKline Pharmaceuticals Limited

  • Jubilant Pharmova Limited

  • Tarsons Products Limited

  • Healthcare Global Enterprises Limited

  • Net Current Assets

  • Cash Margin - CCIL

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Plastic Products

View More

Fund Manager

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 01-Jan-2013 and currently has an AUM of ₹4,267.60 crore. Nippon India Pharma Fund is benchmarked against S&P BSE Health Care - TRI as primary index and S&P BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended down ₹-0.64(-0.22%)yesterday to ₹289.9435.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan and Kinjal Desai.

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097